Skip to main content
Sharon L. Mulvagh on Muck Rack

Sharon L. Mulvagh

Halifax, Nova Scotia
As seen in: JAMA Cardiology, JACC (Journal of the American College of Cardiology), Citeline, Canadian Journal of Cardiology, Journal of The American Society of Echocardiography, CJC Open
Cardiologist, Echocardiographer, Mom, marathoner, grape-grower, Dalhousie Univ Prof of Medicine, Mayo Clinic Prof Emeritus, Past-President @CSEchoCa
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Sharon L.

Contact Sharon L., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes : A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial

|
By Sharon L. Mulvagh
| JAMA Cardiology
Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial Supplement 1. Trial Protocol and Statistical Analysis Plan Supplement 2. eFigure 1. Disposition of Participants in SOUL and the Current Study Subgroup Analyses eFigure 2. Change From Baseline in Blood Pressure Over Time, In-Trial, and First On-Treatment Analysis eFigure 3.
Open in Who Shared Issue with article?

Ozempic pill improves range of cardiometabolic risk factors in type 2 diabetes

|
By Michael Monostra Verified, Richard Smith, Sharon L. Mulvagh
| Citeline Verified
Ask a clinical question and tap into Healio AI's knowledge base. Key takeaways: Oral semaglutide was linked to greater reductions in systolic blood pressure and pulse pressure compared with placebo. Adults receiving semaglutide had larger improvements in triglycerides and total cholesterol. Oral semaglutide improved multiple cardiometabolic metrics among adults with type 2 diabetes at high risk for atherosclerotic cardiovascular disease, according to a post hoc secondary analysis of the SOUL trial.
Open in Who Shared View Duplicates (2) Issue with article?

Ozempic pill improves range of cardiometabolic risk factors in type 2 diabetes

|
By Michael Monostra Verified, Richard Smith, Sharon L. Mulvagh
| Citeline Verified
Ask a clinical question and tap into Healio AI's knowledge base. Key takeaways: Oral semaglutide was linked to greater reductions in systolic blood pressure and pulse pressure compared with placebo. Adults receiving semaglutide had larger improvements in triglycerides and total cholesterol. Oral semaglutide improved multiple cardiometabolic metrics among adults with type 2 diabetes at high risk for atherosclerotic cardiovascular disease, according to a post hoc secondary analysis of the SOUL trial.
Open in Who Shared Issue with article?
See all 14 articles